KEYTRUDA (Pembrolizumab) Plus Chemoradiotherapy Reduces Mortality Risk by 33% in High-Risk Locally Advanced Cervical Cancer

Study Findings:
The Phase 3 KEYNOTE-A18 trial demonstrated that KEYTRUDA (pembrolizumab) in combination with concurrent chemoradiotherapy (CRT) reduced the risk of death by 33% compared to CRT alone in patients with newly diagnosed high-risk locally advanced cervical cancer.

Survival Rates:
At a median follow-up of 29.9 months, the 36-month overall survival (OS) rate was 82.6% for patients receiving the KEYTRUDA-based regimen versus 74.8% for those receiving CRT alone.

Clinical Significance:
This study is the first to show a statistically significant and clinically meaningful improvement in overall survival for an immunotherapy-based regimen in this patient population, potentially changing the treatment paradigm.

Safety Profile:
The safety profile of KEYTRUDA in this trial was consistent with previously reported studies, with no new safety signals identified.

Global Impact:
Cervical cancer is a leading cause of cancer-related deaths in women worldwide, and these findings offer a new standard of care for high-risk locally advanced cervical cancer patients.